Redx Pharma plc Posting of Annual Accounts & AGM notice (5823E)
February 12 2018 - 4:23AM
UK Regulatory
TIDMREDX
RNS Number : 5823E
Redx Pharma plc
12 February 2018
12 February 2018
REDX PHARMA PLC
("Redx" or "the Company")
Notice of Annual General Meeting, posting of Annual Report and
Accounts
Redx Pharma, the drug discovery and development company focused
on cancer and fibrosis, announces that its Annual General Meeting
will be held at 2.00pm on 6 March 2018 at Redx Pharma Plc,
Mereside, Alderley Park, Macclesfield SK10 4TG.
Following the announcement of the preliminary results for the
financial year ended 30 September 2017 on 20 December 2017, the
Company announces that the Annual Report and Accounts and notice of
Annual General Meeting have now been posted to shareholders. The
Annual Report and Accounts is also available to view on Redx's
website at www.redxpharma.com.
For further information, please contact:
Redx Pharma Plc T: +44 1625
469 918
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated T: +44 20
Advisor & Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
FTI Consulting T: +44 20
3727 1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on
AIM (AIM:REDX). Redx is focused on creating and developing first,
or potentially best in class drugs, in specific areas of cancer and
fibrosis that address significant unmet medical need. Redx has an
in-house discovery team with proven world-class chemistry
capabilities.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOALLFFIFLIFLIT
(END) Dow Jones Newswires
February 12, 2018 05:23 ET (10:23 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024